Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Subjects
NCT07346027Phase 1Active, not recruiting
- Sponsor
- Novagains Biopharmaceutical
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of F-02-2-Na in hyperuricemia and gout (2 arms), sponsored by Novagains Biopharmaceutical. Primary endpoints: Adverse Events at 72 hours, Proportion of subjects using Concomitant Medications at 72 hours and 8 more. Started Jun 2026; status: active, not recruiting.
02
Drugs
F-02-2-Na
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT07346027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346027.